Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares. The shares were sold at a weighted average price of $4.6015 per share on May 19, 2026, to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026.
According to the disclosure, these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. Following this transaction, Xu directly holds 626,280 Ordinary Shares.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 Ordinary Shares in an open-market transaction at a weighted average price of $4.6049 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.
The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this transaction, Camblong directly holds 3,629,495 Ordinary Shares.
SOPHiA GENETICS SA’s Chief Medical Officer, Philippe Menu, sold 608 Ordinary Shares of the company on May 19, 2026 at a weighted average price of $4.6059 per share. According to the disclosure, these shares were sold in the open market solely to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary. Following this sale, Menu directly holds 255,780 Ordinary Shares.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported an open-market sale of 684 Ordinary Shares at a weighted average price of $4.6042 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations from vesting restricted stock units under a pre-established Rule 10b5-1(c) trading plan and was not discretionary. Following this transaction, Van Well directly holds 345,052 Ordinary Shares.
SOPHiA GENETICS SA’s Chief People Officer, Manuela Valente, reported a small tax-related share sale. On May 19, 2026, she sold 380 Ordinary Shares at a weighted average price of $4.5985 per share, in open-market transactions.
The footnotes explain that these shares were sold solely to cover tax withholding obligations from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, she directly holds 214,691 Ordinary Shares.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. He sold 33 ordinary shares in an open-market transaction at $4.5424 per share to satisfy tax obligations from restricted stock units vesting on May 18, 2026. Following this sell-to-cover transaction, he directly holds 148,164 ordinary shares.
SOPH: Notice of proposed sales by JURGI CAMBLONG under pre-arranged 10b5-1 plans. The filing lists multiple 10b5-1 sales of Common stock on dates in March–May 2026. The record shows Founders Shares: 8,500 (03/18/2021) and Restricted Stock Units: 4,486 (05/18/2026) identified in the securities-to-be-sold section. The excerpt includes transaction examples, including 04/14/2026: 43,129 shares for $213,833.58 and 05/11/2026: 8,500 shares for $43,241.20. The entries are described as 10b5-1 Sales with per-sale share counts and gross proceeds recorded.
Manuela Valente submitted a Form 144 reporting proposed sales of Common Stock and an offer of Restricted Stock Units. The filing lists an offer of 380 Restricted Stock Units dated 05/18/2026 and multiple 10b5-1 sale transactions dated in 03/19/2026 through 04/20/2026.
SOPH affiliate submitted a Form 144 reporting proposed and recent sales of Common Stock under Rule 144 and 10b5-1 transactions. The filing lists restricted stock unit grants of 608 shares (05/18/2026) and 15,000 RSUs (04/02/2025). It also itemizes multiple 10b5-1 sales by Philippe Menu, including 5,000-share trades on 05/12/2026 and other dates with dollar proceeds shown per trade.
Rule 144 notice relates to the proposed sale of 761 restricted stock units reported with a trade date of 05/18/2026 and a filing line dated 05/19/2026. The filing lists multiple prior 10b5-1 sales by Ross J Muken between 03/19/2026 and 04/20/2026, including transactions of 4,442 shares on 04/13/2026 ($21,166.13).